| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/150-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | PSAP; PSPA; SP-A; SPA2; PSP-A; SFTP1; SP-2A; SPAII; COLEC5; SFTPA2B |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human SFTPA2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SFTPA2抗体的3篇参考文献，按文献名称、作者及摘要内容简要概括：
---
1. **文献名称**: *Autoantibodies against surfactant protein A in idiopathic pulmonary fibrosis*
**作者**: Yang IV, et al.
**摘要**: 研究检测了特发性肺纤维化(IPF)患者血清中抗SFTPA2自身抗体的存在，发现其与疾病严重程度和预后不良相关，提示该抗体可能参与IPF的免疫病理机制。
---
2. **文献名称**: *Anti-surfactant protein A antibodies in interstitial lung disease*
**作者**: Kinder BW, et al.
**摘要**: 探讨间质性肺病(ILD)患者中抗SFTPA2抗体的出现频率及临床意义，发现部分患者抗体阳性，可能与肺泡上皮损伤及异常免疫反应有关。
---
3. **文献名称**: *Surfactant protein A2 antibodies as a biomarker for pulmonary alveolar proteinosis*
**作者**: Uchida K, et al.
**摘要**: 提出抗SFTPA2抗体可作为肺泡蛋白沉积症(PAP)的潜在生物标志物，研究显示抗体水平升高与肺泡表面活性物质代谢紊乱相关，可能指导临床诊断。
---
注：以上文献为示例，实际研究中建议通过PubMed或Web of Science检索最新论文以获取准确信息。
Surfactant Protein A2 (SFTPA2) is a member of the surfactant protein family, primarily expressed in the lung alveoli, where it plays a critical role in pulmonary immune defense and surfactant homeostasis. As a collectin protein, SFTPA2 binds to pathogens, facilitates their opsonization, and modulates inflammatory responses by interacting with immune cells like alveolar macrophages. It also contributes to maintaining lung structure by regulating surfactant lipid metabolism.
Antibodies targeting SFTPA2 are essential tools in research and diagnostics. They help detect SFTPA2 expression levels in tissues or biological fluids, aiding studies on lung diseases such as idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), and lung cancer. Dysregulation of SFTPA2 is linked to these pathologies, with mutations in the *SFTPA2* gene associated with familial pulmonary fibrosis.
Autoantibodies against SFTPA2 have been reported in autoimmune-related interstitial lung diseases, suggesting their potential role as biomarkers. Commercial SFTPA2 antibodies are widely used in techniques like immunohistochemistry, ELISA, and Western blot to investigate disease mechanisms or validate experimental models. However, their clinical utility remains exploratory, with ongoing studies focusing on clarifying their pathogenic or protective roles in lung disorders.
×
